Envestnet Asset Management Inc. bought a new position in Qiagen N.V. (NYSE:QGEN - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 336,095 shares of the company's stock, valued at approximately $13,463,000. Envestnet Asset Management Inc. owned approximately 0.15% of Qiagen as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Groupama Asset Managment grew its holdings in Qiagen by 8,074.0% during the 4th quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after acquiring an additional 32,216,761 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Qiagen by 9.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock valued at $1,127,470,000 after purchasing an additional 2,202,040 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Qiagen by 2.5% in the 4th quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company's stock valued at $970,534,000 after purchasing an additional 531,362 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Qiagen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock valued at $397,937,000 after purchasing an additional 77,119 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Qiagen in the 4th quarter valued at $181,529,000. Institutional investors and hedge funds own 70.00% of the company's stock.
Qiagen Price Performance
Shares of QGEN traded up $0.11 during trading hours on Friday, reaching $48.35. 2,726,997 shares of the company's stock traded hands, compared to its average volume of 1,224,863. The stock has a market cap of $10.75 billion, a PE ratio of 121.23, a price-to-earnings-growth ratio of 2.46 and a beta of 0.68. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. The firm's 50 day simple moving average is $45.95 and its 200-day simple moving average is $42.98. Qiagen N.V. has a 12 month low of $37.63 and a 12 month high of $49.30.
Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The company had revenue of $483.46 million for the quarter, compared to analysts' expectations of $465.66 million. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. Qiagen's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $0.44 EPS. Equities analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.
Qiagen Announces Dividend
The firm also recently announced a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a dividend yield of 0.52%. Qiagen's dividend payout ratio (DPR) is presently 62.50%.
Wall Street Analysts Forecast Growth
QGEN has been the topic of a number of analyst reports. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Barclays initiated coverage on shares of Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. Wall Street Zen upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Robert W. Baird upped their price objective on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Finally, Bank of America upped their price objective on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Seven analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $49.40.
Read Our Latest Analysis on QGEN
About Qiagen
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Further Reading
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
